|

Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer

RECRUITINGSponsored by Hepatopancreatobiliary Surgery Institute of Gansu Province
Actively Recruiting
SponsorHepatopancreatobiliary Surgery Institute of Gansu Province
Started2025-07-29
Est. completion2026-12-29
Eligibility
Age18 Years – 85 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07091526

Summary

This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.

Eligibility

Age: 18 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients with pathologically confirmed pancreatic cancer (primary)
* Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy）
* The postoperative survival time was at least 6 weeks

Exclusion Criteria:

* No surgery was performed, or only palliative surgery/ biopsy was performed
* Patients who underwent emergency hemodialysis or plasma exchange after surgery
* History of gout or long-term urate-lowering therapy, such as allopurinol
* Patients are missing follow-up data
* Hydrochlorothiazide and furosemide were used
* Chronic kidney disease
* Oncolytic syndrome
* Hemolytic anemia
* Lead poisoning
* Hyperparathyroidism
* Hypothyroidism
* A tyrosinase inhibitor was used
* Patients with nonpancreatic primary tumors
* Pregnant or postpartum women.

Conditions2

CancerSerum Uric Acid

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.